FDA approves Merck's Capvaxive for children at higher pneumonia risk

June 18, 2026 6:45 AM

The U.S. Food and Drug Administration has approved an expanded indication for Merck's (NYSE: MRK) Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found